Powder: -20°C for 3 years
In solvent: -80°C for 2 years
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, <a href="/target/ERK" style="display: inline; color: #c13a36">ERK</a> and <a href="/target/Akt" style="display: inline; color: #c13a36">Akt</a> activation in vitro and in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 54.00 | |
2 mg | In stock | $ 84.00 | |
5 mg | In stock | $ 128.00 | |
10 mg | In stock | $ 216.00 | |
25 mg | In stock | $ 515.00 | |
50 mg | In stock | $ 882.00 | |
100 mg | In stock | $ 1,552.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 135.00 |
Description | LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo. |
In vitro | LM22B-10 shows maximum neurotrophic survival activity levels that are higher than those maximally achieved with BDNF (53 ± 7.2% above BDNF at 0.7 nM) and NT-3 (91 ± 8.6% above NT-3 at 0.7 nM) with an EC50 value of 200-300 nM. LM22B-10 (1000 nM) induces neurites of significantly larger average lengths, up to -40 μM. LM22B-10 (250-2000 nM) binds to TrkB-Fc and TrkC-Fc in a dose-dependent manner. LM22B-10 inhibits binding of BDNF to TrkB-expressing cells and NT-3 to TrkC-expressing cells. LM22B-10 promotes cell survival and functions preferentially through TrkB and TrkC. LM22B-10, but not BDNF or NT-3, promotes neurite outgrowth in an inhibitory environment. LM22B-10 induces patterns of Trk and downstream signaling activation that are distinct from those of BDNF and NT-3. LM22B-10 also induces TrkB, TrkC, AKT and ERK activation in hippocampal neurons in culture[1]. |
In vivo | LM22B-10 (0.5 mg/kg) activates TrkB, TrkC, AKT and ERK in C57BL/6J mice. LM22B-10 (50 mg/kg, i.p.) shows increased phosphorylation at TrkBY817 and TrkCY820. LM22B-10 activates synaptic TrkB and TrkC and increases pre- and post-synaptic proteins and spine density in aged mice [1]. |
Cell Research | Mouse NIH-3T3 cells, mouse NIH-3T3 cells expressing TrkA (NIH-3T3-TrkA) or p75NTR (NIH-3T3-p75NTR), and NIH-3T3 cells expressing TrkB (NIH-3T3-TrkB) or TrkC (NIH-3T3-TrkC) are propagated in DMEM supplemented with 10% FBS and 200-400 μg/mL Geneticin (for Trk-expressing cells) or 400 μg/mL hygromycin (for p75NTR-expressing cells). Cells are seeded into 24-well plates (30,000 cells/well) and cultured in medium consisting of 50% PBS and 50% DMEM without supplements. Following exposure to growth factors (0.7 nM) or 1000 nM LM22B-10 for 72-96 h, cells are suspended in 50 μL lysis buffer, transferred to opaque 96-well culture plates and survival is measured using the ViaLight Assay. |
Synonyms | LM22B10 |
Molecular Weight | 485.02 |
Formula | C27H33ClN2O4 |
CAS No. | 342777-54-2 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: 4.5 mg/mL
DMSO: 45 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LM22B-10 342777-54-2 Cytoskeletal Signaling MAPK PI3K/Akt/mTOR signaling Tyrosine Kinase/Adaptors Akt Trk receptor ERK inhibit Trk Receptor LM-22B-10 LM22B10 LM22B 10 Tropomyosin related kinase receptor PKB Inhibitor Protein kinase B Extracellular signal regulated kinases inhibitor